Weekly Digest - 29 Apr-05 May 2023
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - 29 Apr-05 May 2023
May 03, 2023: Breyanzi (IV) / R/R Large B-cell Lymphoma / BMS: Received EU approval
EU approval of Breyanzi was based on the positive data from the pivotal Phase 3 TRANSFORM study evaluating Breyanzi in comparison to SOC
It demonstrated statistically significant and clinically meaningful improvements in the study’s primary endpoint of event-free survival (EFS)
- 10.1 months vs. 2.3 months
It has a manageable and well-established safety profile
- Any-grade CRS: 48.9%
- Grade 3 CRS: 1%
- “This marks the approval of our third indication in Europe for our CAR T cell therapy portfolio, underscoring our continued drive to deliver the promise of cell therapy with curative potential for more patients.” said Anne Kerber, senior vice president, head of Cell Therapy Development, Bristol Myers Squibb
